Stable-Isotope Dilution HPLC-Electrospray Ionization Tandem Mass Spectrometry Method for Quantifying Hydroxyurea in Dried Blood Samples
Marahatta et al.
The finding, in our words
An LC-MS/MS method accurately quantified hydroxyurea from small volumes of dried blood collected on DMPK-C cards and VAMS devices across a linear range of 0.5 to 60 μg/mL with comparable performance. This enables therapeutic drug monitoring and pharmacokinetic assessment in pediatric sickle cell anemia patients using capillary heel- or finger-prick sampling.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This review summarises liquid chromatography with tandem mass spectrometry assays using dried blood spots and volumetric absorptive microsampling for quantifying antimicrobial drugs in children, highlighting that VAMS reduces haematocrit bias and offers a viable alternative to traditional plasma sampling for therapeutic drug monitoring.
The validated LC-MS/MS method showed similar pharmacokinetic profiles for albendazole and its metabolites across plasma, whole blood, dried blood spots and Mitra microsamples from hookworm-infected adolescents, supporting microsampling for paediatric pharmacokinetic studies. Mitra extraction proved more robust than dried blood spots during validation and is recommended for future albendazole pharmacokinetic work, despite higher albendazole sulfone concentrations observed in both microsampling devices compared with wet matrices.
A VAMS-LC-MS/MS method was developed and validated for measuring four antibiotics in 10 microlitres of human blood, showing that VAMS provided accurate quantification unaffected by haematocrit, unlike dried blood spots. The method was applied to paediatric patient samples, supporting its use for therapeutic drug monitoring in children.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
This study employed volumetric absorptive microsampling to collect blood samples from neonates, revealing that existing propofol pharmacokinetic models poorly predicted drug levels in this population. A newly developed meta-model provided accurate predictions, validating the use of patient-centric microsampling for therapeutic drug monitoring in preterm and term infants.